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Abstract: The fungal genus Pyrenochaetopsis is commonly found in soil, terrestrial, and marine
environments, however, has received little attention as a source of bioactive secondary metabolites
so far. In a recent work, we reported the isolation and characterization of three new anticancer
decalinoyltetramic acid derivatives, pyrenosetins A–C, from the Baltic Fucus vesiculosus-derived
endophytic fungus Pyrenochaetopsis sp. FVE-001. Herein we report a new pentacyclic
decalinoylspirotetramic acid derivative, pyrenosetin D (1), along with two known decalin derivatives
wakodecalines A (2) and B (3) from another endophytic strain Pyrenochaetopsis FVE-087 isolated from
the same seaweed and showed anticancer activity in initial screenings. The chemical structures of the
purified compounds were elucidated by comprehensive analysis of HR-ESIMS, FT-IR, [α]D, 1D and
2D NMR data coupled with DFT calculations of NMR parameters and optical rotation. Compounds
1–3 were evaluated for their anticancer and toxic potentials against the human malignant melanoma
cell line (A-375) and the non-cancerous keratinocyte cell line (HaCaT). Pyrenosetin D (1) showed
toxicity towards both A-375 and HaCaT cells with IC50 values of 77.5 and 39.3 µM, respectively, while
2 and 3 were inactive. This is the third chemical study performed on the fungal genus Pyrenochaetopsis
and the first report of a pentacyclic decalin ring system from the fungal genus Pyrenochaetopsis.
Keywords: Pyrenochaetopsis; pyrenosetin; marine fungus; decalinoyltetramic acid; Fucus vesiculosus;
anticancer
1. Introduction
Seaweeds harbor diverse microbial communities, such as bacteria, fungi, bacteriophage,
and viruses, forming a complex holobiont [1–3]. Endophytic fungi are one of the predominant
microbial communities associated with seaweeds and are gaining growing interest as a source of small
molecule natural products with high chemical diversity and wide-ranging bioactivity profiles [4].
Over the past decades, several structurally unique metabolites from different classes of natural products,
such as polyketides [5], terpenes [6], steroids [7], non-ribosomal peptides [8], and alkaloids [9] were
Mar. Drugs 2020, 18, 281; doi:10.3390/md18060281 www.mdpi.com/journal/marinedrugs
Mar. Drugs 2020, 18, 281 2 of 12
reported from seaweed-derived (algicolous) fungi, with multiple bioactivities, including anticancer [7],
antibiotic [9], and antioxidant [10].
Fungal metabolites with a ‘decalin ring system’ represent a large group of architecturally complex
structural scaffolds [11]. The decalin ring system is usually substituted with, e.g., a terpene side
chain [12] or γ-lactam [13], pyrone [14], diene [15], pyrrolizidine [16], and tetramic acid rings [17].
Decalin derivatives are also intriguing for their remarkable biological activities, including anticancer [18],
antiviral [19], and antimicrobial [20]. So far, several decalin derivatives with multiple ring systems
(e.g., tricyclic ring system [21]) or rare functional groups (e.g., deoxytetramic acid [17]) have been
isolated from different algicolous fungi. As an example, Ascochyta salicorniae, an endophytic fungus
derived from the green seaweed Ulva sp. yielded ascosalipyrrolidinones A and B, unusual decalin
derivatives with an ether function on the terminal tetramic acid [17]. Ascosalipyrrolidinone A is a
potent antiplasmodial agent that inhibits both the drug-resistant and the drug-sensitive Plasmodium
falciparum strains K1 and NF54 (IC50 736 and 378 ng/mL, respectively). It also shows antimicrobial and
tyrosine kinase inhibiting activities [17].
As part of our on-going project aiming to investigate the cultivable mycobiome of seaweeds,
we have previously isolated 55 epiphytic and endophytic fungi from the Baltic brown alga
Fucus vesiculosus [22]. In-depth chemical investigation of the endophytic fungus Pyrenochaetopsis
sp. FVE-001 by using a bioactivity-based molecular networking approach led to the rapid isolation
and characterization of three new decalinoylspirotetramic acid derivatives pyrenosetins A–C and the
known decalin phomasetin [23]. All four compounds showed notable activity against human malignant
melanoma cancer cells (A-375) [23]. In the continuation of our search for new anticancer metabolites
from Fucus vesiculosis-associated fungi, a second strain of Pyrenochaetopsis sp. FVE-087 attracted our
attention. In preliminary screenings, the crude extract of this strain also exerted potent anticancer
activity [22]. Chemical work-up of this endophyte monitored by anticancer activity against the same
melanoma cell line (A-375) resulted in the purification of a new pentacyclic decalinoyltetramic acid
derivative, pyrenosetin D (1), along with two known decalins wakodecaline A (2) and wakodecaline B
(3). In this study, we report the isolation, detailed structure elucidation, the anticancer activity, and the
toxicity of compounds 1–3.
2. Results
2.1. Strain Identification and Cultivation
The endophytic fungus FVE-087 (GenBank accession number: MH881502) was isolated from the
inner thallus of the brown alga Fucus vesiculosus collected at Kiel Fjord (Baltic Sea, Germany). The initial
taxonomic study of FVE-087 revealed its taxonomical identity at order level, i.e., Pleosporales [22].
The re-amplification of ITS1-5.8S rRNA gene-ITS2 region yielded a longer 408 bp fragment, which
enabled its identification at the genus level. A phylogenetic tree was constructed using the nucleotide
sequences for related strains (obtained from NCBI database) including the previously identified
Pyrenochaetopsis sp. FVE-001 from the same seaweed, indicating that the fungus FVE-087 was a close
relative of the co-existing fungus Pyrenochaetopsis sp. FVE-001. Based on the phylogenetic tree analysis
(Figure S1), the strain FVE-087 was confirmed to be a Pyrenochaetopsis sp. The fungus FVE-087 was
cultivated in the same manner as described in our previous study [23], i.e., in liquid potato dextrose
medium (PDM) at 22 ◦C for 14 days under continuous shaking.
2.2. Extraction, Bioactivity Testing, and Isolation
The culture broth (24 L) was extracted with EtOAc. The crude EtOAc extract of the fungus was
subjected to a modified Kupchan partitioning scheme to yield n-hexane (KH), CHCl3 (KC), and aqueous
MeOH (KM) subextracts. All three subextracts were tested for their activity against five cancer cell lines;
malignant melanoma (A-375), lung carcinoma (A-549), colorectal adenocarcinoma (HT-29), colorectal
carcinoma (HCT-116), and breast cancer cell line (MDA-MB-231). The KC subextract showed the
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highest inhibitory activity against all tested cell lines (>84% cell growth inhibition at 100 µg/mL) and
was selected for a detailed chemical work-up. The KC subextract was fractionated on a C18 SPE
cartridge using a 10% gradient of MeOH in water. This yielded 11 subfractions, and the anticancer
activity was tracked to late fractions 7–9 (Table S6). Reversed-phase HPLC purification of the fractions
7 and 8, monitored by the anticancer activity against malignant melanoma (A-375) cells, afforded
compounds 1–3 (Figure 1).
Figure 1. Chemical structures of compounds 1–4.
2.3. Structure Elucidation
Compound 1 was obtained as a colorless oil. The molecular formula C25H35NO6 that required
nine degrees of unsaturation (DoU) was assigned based on the HR-ESIMS spectrum of 1 (Figure S10).
The FT-IR spectrum (Figure S11) indicated the presence of hydroxyl (vmax 3226–3560 cm-1), carbonyl
(vmax 1679 and 1734 cm-1) and aliphatic ether (vmax 1064 and 1159 cm-1) functions. Comprehensive
analysis of the 1H NMR data in conjunction with the DEPT-HSQC spectrum (CD3CN, Table 1,
Figures S4 and S6) revealed the presence of five methyl groups, including one secondary (H3-19, δH
0.89, d, J = 6.6 Hz), one tertiary ( H3-12, δH 0.88, s), one olefinic (H3-18, δH 1.76, br s), one methylketone
(H3-17, δH 2.09, s), plus an N-methyl (H3-7′, δH 2.86, s) signal. In addition, also observed were five
pairs of diastereotopic methylene protons, namely H2-7 (δH 0.75, q, J = 11.9 Hz and 1.82, m), H2-9 (δH
0.83, dq, J = 2.7, 12.6 Hz and 1.71, m), H2-10 (δH 1.02, m and 1.29, dq, J = 12.9, 3.0 Hz), H2-15 (δH 2.52,
dd, J = 16.2, 9.4 Hz and δH 2.70, dd, J = 16.2, 3.1 Hz), and the oxymethylene protons of H2-6′ (δH 3.79,
dd, J = 11.6, 6.4 Hz and δH 3.86, dd, J = 11.6, 4.1 Hz). The 1H NMR spectrum also comprised signals
belonging to eight methine protons; this included six aliphatic methine protons which were assigned
to H-3 (δH 2.32, d, J = 10.0 Hz), H-6 (δH 1.84, m), H-8 (1.44, m), H-11 (1.48, ddd, J = 11.8, 10.5, 2.7 Hz),
H-13 (δH 2.67, dd, J = 10.1, 3.4 Hz), H-5′ (δH 3.44, dd, J = 7.0, 4.1 Hz), plus one olefinic methine proton
that appeared as a broad singlet at δH 5.25 (H-5) and an oxymethine proton that resonated at δH 4.90
(H-14, dt, J = 9.3, 3.3 Hz) (Table 1). The 13C NMR spectrum of 1 (Table 1, Figure S5) contained 25 signals
accounting for three carbonyls δC 170.2 (C-2′), 206.8 (C-16), and 213.2 (C-1), and two olefinic carbons at
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δC 128.0 (C-5), and 133.2 (C-4), accounting for four DoU. This indicated 1 to be a pentacyclic compound.
Comparison of the NMR data of 1 with those of tetracyclic decalinoylspirotetramic acid derivatives
pyrenosetins A–C [23] indicated close similarities. Thus, 1 was identified as a pyrenosetin-type
decalinoylspirotetramic acid with an additional ring system.
Table 1. 1H NMR (600 MHz) and 13C NMR (150 MHz) data of compound 1 (CD3CN).
No.
1
δH, mult (J in Hz) δC
1 - 213.2
2 - 56.4
3 2.32, d (10.0) 54.8
4 - 133.2
5 5.25, br s 128.0
6 1.84, m 37.7
7 eq 1.82, m 42.9
ax 0.75, q (11.9)
8 1.44, m 33.5
9 eq 1.71, m 36.0
ax 0.83, dq (2.7, 12.6)
10 eq 1.29, dq (12.9, 3.0) 25.8
ax 1.02, m
11 1.48, ddd (11.8, 10.5, 2.7) 37.9
12 0.88, s 14.2
13 2.67, dd (10.1, 3.4) 57.0
14 4.90, dt (9.3, 3.3) 83.7
15 a 2.70, dd (16.2, 3.1) 50.3
b 2.52, dd (16.2, 9.4)
16 - 206.8
17 2.09, s 30.8
18 1.76, br s 23.2
19 0.89, d (6.6) 22.5
2′ - 170.2
3′ - 75.3
4′ - 110.3
5′ 3.44, dd (7.0, 4.1) 68.3
6′ a 3.86, dd (11.6, 4.1) 60.4
b 3.79, dd (11.6, 6.4)
7′ 2.86, s 29.5
In order to identify the position of the fifth ring system and the complete planar structure of 1,
we undertook DQF-COSY and HMBC experiments. The 1H-1H COSY spectrum of 1 comprised three
spin systems (a–c) (Figure 2A and Figure S7). The largest spin system (a) started with the olefinic
proton H-5 that coupled with H-6, then included the methyl substituted cyclohexane moiety that
terminated with the H-11. The latter proton was in turn coupled with H-6, while H3-19 coupled with
H-8, completing the structure of the ring A with a secondary methyl group attached at C-8. Further
detected in the COSY spectrum was a short spin system (b) that corresponded to a hydroxyethyl
group (H-5′ to H-6′). The final proton network (c) covered the protons of H-3, H-13, H-14, and H2-15
(Figure 2A and Figure S7).
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Figure 2. (A) Key COSY (bold) and HMBC (blue) correlations within 1. a–c: Spin systems extracted
from the COSY spectrum. (B) NOESY (red) correlations on the lowest-energy DFT conformer of 1.
In-depth analysis of the 1H-13C HMBC data (Figure 2A and Figure S8) enabled to assemble the
three COSY spin systems with quaternary carbons and heteroatoms, hence completing the full structure
of 1. Firstly, the position of the H3-19 at C-8 (ring A) was further confirmed by the HMBC correlations
between H3-19 with C-7, C-8, and C-9. The ring B of the unsaturated decalin moiety was constructed
on the basis of the HMBC cross-peaks observed from H-3 to C-2, C-4, C-5, and C-11, from H-5 to C-3
and C-11, and from the olefinic methyl group H3-18 to C-3, C-4, and C-5. The tertiary methyl H3-12
was assigned to C-2 based on the key HMBC correlations from H3-12 to C-2, C-3, and C-11. Additional
HMBC correlations between H3-12/C-1, H-3/C-3′, and H-13/C-3′ confirmed the spiro (cyclopentanone)
ring system C (Figure 2A). The ring D comprising of an N-methyl tetramic acid was built with the aid
of the HMBC correlations between H-5′/C-2′, H-5′/C-4′, H-6′/C-4′, H-6′/C-5′, H3-7′/C-2′, H3-7′/C-5′.
The upfield chemical shift of C-4′ (δC 110.3) in comparison to other pyrenosetins, such as pyrenosetin C
(4) suggested the presence in 1 of an acetal or hemiacetal rather than a ketone function. The connection
of the ring D at C-3′ of the ring C was evident due to further HMBC cross-peak seen between H-5′/C-3′.
Pyrenosetins A–C bear a C-16 oxygenated butyl substitution with a double bond ∆14(15) in the
side chain (attached at C-13) [23]. The comparison of the 1H and 13C NMR data of 1 from C-13 to
C-15 (Table 1) with those of pyrenosetin C (4) [23] clearly showed that 1 lacks the double bond at
C-14. Instead, the H-14 was converted to an oxymethine signal (δH 4.90) that showed a diagnostic
HMBC coupling with C-4′ (Figure 2A and Figure S8). This fact, in addition to above mentioned COSY
correlations between H-13/H-14 and H-14/H2-15 confirmed the fifth tetrahydrofuran ring (E). Final
HMBC correlations from H3-17 to C-15 (δC 50.3) and C-16 (δC 206.8) completed the side chain that
ended with a methylketone. Thus, the pentacyclic 2D structure of 1 was established as shown in
Figure 1.
The relative configuration of the stereogenic centers within 1 was deduced based on NOESY
correlations and coupling constant analysis (Figure 2B and Figure S9). The two large axial-axial
couplings experienced by H-11 (ddd, J = 11.8, 10.5, and 2.7 Hz) established the trans junction between
rings A and B. The observed NOESY correlations between H-3/H3-12, H-3/H-14, H-6/H-8, H-6/H3-12,
and H-11/H-13 indicated the α-orientation of H-3, H-6, H-8, H3-12, H-14, and the β-orientation of
H-11, H-13, and the H3-19 methyl group. This left three stereogenic centers (C-3′, C-4′, and C-5′) in the
tetramic acid moiety to be assigned.
Assignment of configuration at C-3‘ and C-4′ was based on the high geometric strain of
trans-5,5-fused ring systems, which are known to be less stable than their cis counterparts by more
than 6 kcal/mol [24]. As the hemiacetal function at C-4′ would readily open in case of steric strain,
the possibility of strained trans junctions between rings C and E and/or between rings E and D was
ruled out, and the requirement of cis junctions between rings C, E, and D defined configurations at
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C-3′ and C-4′ as depicted in structure 1. The configuration at C-5′ was suggested by a very weak NOE
correlation between H-5′ and H-15b (δH 2.52) (Figure 2B).
As the determined configuration at C-3′ was opposite to that found in the other pyrenosetin
analogues (including compound 4), and configuration at C-5′ was only based on a single weak NOE
correlation, the structure of 1 was validated using DFT prediction of NMR parameters. Compound
1, its epimer at C-3′, namely 3′-epi-1 (which has also opposite configuration at C-4′, to keep the
cis junction between rings D and E), and its epimer at C-5′, namely 5′-epi-1 were considered for
calculations (see Supplementary Figure S2 for structures, and Materials and Methods Section for details
on computational methods). After a molecular dynamics-based conformational search, conformers
were optimized at the B3LYP/TZVP/SMD level; then, 1H and 13C isotropic shieldings were calculated,
respectively, at the WP04/aug-cc-pVDZ/PCM and mPW1PW91/6-311+G(2d,p) levels of theory, and
scaled to chemical shifts using the linear regression method [25]. Calculations on 3′-epi-1 were
soon stopped, because optimized conformers showed energies constantly higher than 1 by more
than 10 kcal/mol (as expected, because of the strained trans junction between rings C and E) and
root-mean-square deviations (RMSD) of 13C NMR chemical shifts of rings C, D, and E constantly over
6 ppm. In contrast, chemical shifts calculated for compound 1 were in excellent agreement with the
experimental values (RMSD of 1.66 ppm for 13C and 0.076 for 1H). While this results provided solid
support to the overall structure of 1 and to configurations at C-3′ and C-4′, they did not support the
assignment of the configuration at C-5′, because chemical shifts of 5′-epi-1 also showed a comparable
agreement with the experiment (RMSD of 1.69 ppm for 13C and 0.077 ppm for 1H) (Figure S3). Even
restricting the comparison to atoms of ring D and/or using DP4+ analysis [26], no clear-cut answer
about configuration at C-5′ could be obtained from the predicted chemical shifts. Therefore, coupling
constants were examined.
Analysis of structures 1 and 5′-epi-1 showed that the main difference between the two compounds
was expected in the 1H-13C coupling constants of H-5′. In particular, the coupling constant between
H-5′ and C-2′ was calculated as 4.3 Hz for 1 and 0.6 Hz for 5′-epi-1 (Table S5). When not measured
directly, 1H-13C coupling constants can be estimated from the intensity of the corresponding HMBC
peaks, an intense peak indicating a relatively large JCH [27]. The prominent correlation peak observed
between H-5′ and C-2′ was not consistent with the small 0.6 Hz coupling constant predicted for 5′-epi-1,
and conclusively determined the relative stereochemistry of pyrenosetin D as in structure 1. Finally,
the observed weak NOE correlation between H-5 and H-15b was in good agreement with the distance
between 3.96 and 4.16 Å of these protons measured for the DFT optimized conformers of 1 (Figure 2B).
The absolute configuration of compound 1 was determined on the basis of its predicted optical
rotation (OR). DFT prediction of OR is a valuable, although not as general, alternative to ECD for
determining the absolute configuration of natural products, and can be reliably used for this purpose
provided that (i) the magnitude of the measured OR is not close to zero and (ii) the sign of the calculated
OR is the same for all, or at least for most conformers [28]. The OR of compound 1 was predicted
at the B3LYP/TZVP/PCM(MeOH) level of theory; the calculated [α]D (as the Boltzmann average of
individual conformers) was -104, compared to the experimental value -56. In addition, the OR values
calculated for individual conformers were all negative, and with similar magnitude. These results
strongly supported the absolute configuration of pyrenosetin D as shown in Figure 1.
The known compounds 2 and 3 were identified as wakodecalines A and B (Figure 1), respectively,
based on their HR-ESIMS and MS/MS data, plus by comparison of their 1D/2D NMR and [α]D data
with those reported in the literature [29].
2.4. Bioactivity Tests
Due to the limited availability, compounds 1–3 were tested for their inhibitory activity against
only one cancer cell line, i.e., the human malignant melanoma cell line (A-375). The general toxicity of
the isolated metabolites was assessed against the human keratinocyte cells (HaCaT). Compound 1
exhibited moderate anticancer activity against the A-375 cells (IC50 value 77.5 µM), but it was also
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toxic towards the HaCaT cells (IC50 value of 39.3 µM). The known compounds 2 and 3 did not exert
anticancer or toxic effects, even at the highest test concentration of 200 µM.
3. Discussion
Pyrenochaetopsis is a ubiquitous fungal genus found in both terrestrial and marine
environments [30,31]. However, the members of this genus have remained almost fully unexplored for
their bioactive secondary metabolites. To our knowledge, the very first chemical study was published in
2017 by Nogawa et al. on a Pyrenochaetopsis sp. isolated from a soil sample collected in Japan [29]. This
work reported wakodecalines A, B, two new tricyclic decalin derivatives with a spiro pentanone ring
(C) and N-methylated terminal serine moiety as well as phomasetin, a known decalin compound with
a terminal tetramic acid function [29]. The lack of any other investigation in the literature on chemical
constituents or biological activity has initiated our interest into this unexplored fungal taxon. In a very
recent study, we demonstrated that, when cultured in liquid potato dextrose medium, the algicolous
Pyrenochaetopsis sp. FVE-001 produces pyrenosetins A–C, new tetracyclic decalin derivatives with
good activity against malignant melanoma cells (A-375) [23]. In addition, also isolated and identified
from this fungus was the known compound phomasetin [23].
The ‘decalin’ moiety is a common structural motif in an array of marine fungal natural
products [13,32,33]. It has been proposed that the decalin ring serves as a primary ring system
or a scaffold to form polycyclic metabolites, with bicyclic decalins being the most common [11,13,32–35].
The chemical investigation of the marine sponge-derived fungus Trichoderma harzianum in 1993 led
to the isolation of the first bicyclic decalin derivative trichoharzin isolated from a marine fungus.
Trichoharzin contains rare alkyl and acyl moieties [36]. So far, more than 50 decalin derivatives have
been reported from marine fungi [11,13,32–37]. The marine-derived bicyclic decalin derivatives often
incorporate additional ring systems, e.g., pyrone [37], cyclopentanone [13], and tetramic acid [34] to
lead tricyclic [35,37], tetracyclic [13], and pentacyclic scaffolds [34]. Of all, tetramic acid represents
one of the most common substituents [13,34,38]. Pyrenosetins A–C, which we recently reported from
Pyrenochaetopsis sp. FVE-001, an endophyte of the Baltic brown alga Fucus vesiculosus, represent one of
the most complex tetracyclic decalinoylspirotetramic acids reported to date [23]. Such complex decalin
scaffold is rare in fungi. To our knowledge, only a few fungal genera such as Fusarium sp. [34,39],
Alternaria sp. [13], Diaporthe sp. [40], and Pyrenochaetopsis sp. [23] have been reported to produce such
type of unique molecules. Decalinoyltetramic acid derivatives are also intriguing for remarkable
biological activities they exhibit. For example, altercrasins D and E isolated from sea-urchin-derived
Alternaria sp., have shown potent activity against murine P388 leukemia, human HL-60 leukemia,
and murine L1210 leukemia cell lines [13]. However, most of the decalin derivatives suffer from poor
selectivity, i.e., they also possess toxicity towards non-cancerous cells. This is a common characteristic
of mycotoxins [34,41].
Our previous research on pyrenosetins highlighted the importance of the side chain attached at
C-13 for their bioactivity [23]; both the anticancer activity and the general toxicity were significantly
reduced with the oxidation of the C-16 hydroxyl group to a ketone. Notably, wakodecalines (2 and 3)
that lack the terminal tetramic acid moiety did not show any bioactivity against A-375 cells, even at the
highest test concentrations. This suggests that both side chain and the tetramic acid moiety are crucial
for bioactivity of the decalin derivatives. Additionally, the presence of the additional tetrahydrofuran
ring as found in 1 may be improving the activity against A-375 cells (IC50 77.5 µM) when compared to
the anticancer activity of pyrenosetin C on the same cell line (IC50 140.3 µM) [23]. A previous study
showed that fusarisetin A that possesses a tetrahydrofuran ring exhibits higher activity against the
invasive breast cancer cell line MDA-MB-231 than its precursor equisetin [42].
In conclusion, a new cytotoxic pentacyclic decalinoylspirotetramic acid derivative, pyrenosetin D
(1) and two known and non-toxic tricyclic metabolites, wakodecalines A (2) and B (3), were purified
from the algicolous fungus Pyrenochaetopsis sp. To our knowledge, only fusarisetins that were isolated
from Fusarium sp. possess somehow similar pentacyclic skeleton [34,39]. This is the third study
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performed on the chemical constituents of the fungal genus Pyrenochaetopsis and the first report of a
pentacyclic decalin ring system from Pyrenochaetopsis species. Further investigation of the anticancer
activity, selectivity, and mechanism of cytotoxic action of our metabolites might expand our knowledge
of the structure–activity relationship of decalinoyltetramic acid derivatives.
4. Materials and Methods
4.1. General Procedures
FT-IR spectra were recorded on a PerkinElmer Spectrum Two FT-IR spectrometer (PerkinElmer,
Boston, MA, USA). Specific rotation ([α]D) values were measured in MeOH on a Jasco P-2000 polarimeter
(Jasco, Pfungstadt, Germany). NMR data were recorded on a Bruker AV 600 spectrometer (600 and
150 MHz for 1H and 13C NMR, respectively, Bruker®, Billerica, MA, USA). The residual solvent
signals were detected in NMR spectra as internal references: δH 1.94/δC 118.3 and δC 1.3 (CD3CN).
4-Dimethyl-4-silapentane-1-sulfonic acid (DSS) was used as an internal standard. HRESIMS was
recorded on a microTOF II-high-performance TOF-MS system (Bruker®, Billerica, MA, USA) equipped
with an electrospray ionization source. Solid-phase extraction (SPE) was performed on a C18 cartridge
(50µm, 65Å, Phenomenex, 411 Madrid Avenue, Torrance, CA, USA). HPLC separations were performed
on a VWR Hitachi Chromaster system (VWR International, Allison Park, PA, USA) consisting of a
5430 diode array detector (VWR International, Allison Park, PA, USA), a 5310 column oven, a 5260
autosampler, and a 5110 pump. The eluents used for HPLC separations were milli Q water (A) and
MeCN (B). Routine HPLC separations were performed on a semi-preparative C18 monolithic column
(Onyx, 100 × 10 mm, Phenomenex, Torrance, CA, USA) and an analytical synergi polar-RP 80 Å LC
column (250 × 4.6 mm, Phenomenex, Torrance, CA, USA). The organic solvents used for chemical
analysis were of HPLC grade (ITW Reagents, Germany). An in-house Arium® Water Purification
Systems (Sartorius, Germany) was used for the preparation of milli Q water. Solvents used in extraction,
Kupchan partition, and purification (including EtOAc, n-hexane, MeOH and MeCN) were purchased
from VWR International GmbH (Hannover, Germany). Potato extract and dextrose that used for
fungal cultivation were purchased from Sigma-Aldrich (Schnelldorf, Germany) and Merck (Darmstadt,
Germany), respectively. Agar was purchased from Applichem (Darmstadt, Germany).
4.2. Strain Identification and Cultivation
The fungal strain Pyrenochaetopsis sp. FVE-087 (GenBank accession number: MH881502) was
obtained from Fucus vesiculosus specimens that were collected in Falckenstein Beach (54◦23′22.6′′ N,
10◦11′26.4′′ E), Kiel Fjord, Baltic Sea, in December 2015, Germany [22]. The fungus was identified
by morphological observation, analysis of the ITS1-5.8S rRNA gene-ITS2 region and by building a
phylogenetic tree with 14 related strains including the Pyrenochaetopsis sp. FVE-001, using the method
described in our previous work [23]. The initial cultures were maintained on potato dextrose agar
plates (PDA: potato extract 4 g, dextrose 20 g, agar 15g for 1 L, pH 5.6). After 3 days of pre-cultivation,
pieces of mycelia were cut into small segments and aseptically inoculated into an Erlenmeyer flask
(300 mL) that contained 100 mL of potato dextrose broth media (PDM: potato extract 4 g, dextrose 20 g
for 1 L; pH 5.6). After 7 days inoculation, 1 mL liquid seed was added into Erlenmeyer flasks (2 L),
each containing 800 mL PDM. A 24 L culture broth was fermented at 22 ◦C for 14 days on a rotary
shaker at 120 rpm.
4.3. Extraction and Isolation
The culture broth was partitioned against the same volume of EtOAc twice at room temperature.
The EtOAc phase was evaporated to dryness under reduced pressure to afford 17.64 g yellow oily
extract. The extract was subjected to a modified Kupchan partition scheme to yield three subextracts,
n-hexane (KH, 6.93 g), CHCl3 (KC, 4.57 g), and aqueous MeOH (KM, 440.5 mg). All three subextracts
were tested for their bioactivity against five cancer cell lines and non-cancerous cell line HaCaT. The KC
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subextract showed high anticancer bioactivity against all five cancer cell lines (>84% inhibition rate at
100 µg/mL) and was fractionated on a C18-SPE column eluting with 10% stepwise gradient of MeOH
in water (0–100%) to afford 11 fractions (F0–F10). Anticancer bioactivity was tracked to fractions F7–F9
(Table S6). The fraction 7 (F7, 138 mg) was subjected to semi-preparative RP–HPLC equipped with an
Onyx monolithic C18 column. Elution with a gradient MeCN:H2O mixture (25–35% MeCN over 30 min,
flow 3.0 mL/min) yielded eight subfractions (F7-1 to F7-8). The F7-7 (10.8 mg) was further purified
by RP-HPLC on an analytical synergi polar-RP 80 Å column eluting with MeCN:H2O (52% isocratic
MeCN over 19 min, flow 1.0 mL/min) to yield wakodecaline B (3, 2.4 mg, tR 8.8 min) and pyrenosetin D
(1, 1.2 mg, tR 10.3 min). The subfraction 8 (F8, 369.6 mg) was chromatographed by RP-HPLC equipped
with Onyx monolithic C18 column using MeCN:H2O mixtures (40% isocratic MeCN over 28 min
and gradual increase to 60% MeCN by 40 min, flow 3.0 mL/min) to yield 14 subfractions (F8-1 to
14). Wakodecaline A (2) was tracked to F8-3 (7 mg). This fraction was subjected to RP-HPLC on an
analytical synergi polar-RP 80 Å LC column using an isocratic mixture of MeCN:H2O (45:55) (flow
1.0 mL/min) to yield wakodecaline A (2, 2.9 mg, tR 9.5 min).
Pyrenosetin D (1): Colorless oil; [α]20D −56 (c 0.10, MeOH); IR (oil) vmax 3226-3560, 2947, 2921, 1734,
1679, 1460, 1406, 1377, 1159, 1064 cm−1. 1H NMR (CD3CN, 600 MHz) and 13C NMR (CD3CN, 150 MHz)
are shown in Table 1; HR-ESIMS found m/z 446.2520 [M + H]+, C25H36NO6, calculated for 446.2537.
4.4. Computational Details
Conformational search for 1 and 5′-epi-1 was based on a 10-ns molecular dynamics (MD) simulation
at 600 K as previously described [43]. The MD simulation generated 101 and 102 different conformers
for 1 and 5′-epi-1, respectively, within 5 kcal/mol from the lowest energy conformer. Optimizations
of geometries from MD were performed using density functional theory (DFT) with the Gaussian 16
program [44], the B3LYP functional, the 6-31G(d,p) basis set, and the SMD model for the solvent, ACN.
This resulted in 15 and 17 conformers for 1 and 5′-epi-1, respectively, within 3 kcal/mol from the lowest
energy conformer. Finally, these conformers were further optimized at the B3LYP/TZVP/SMD level of
theory, giving a final set of 10 significantly populated (population > 1% at 298 K) conformers for 1 and 11
significantly populated conformers for 5′-epi-1. Vibrational frequency analysis revealed no imaginary
frequencies, confirming that all conformers were in a true energy minimum. The Cartesian coordinates
and relative energies of the conformers are reported in Tables S1 and S2. These conformational
ensembles were used for all the subsequent calculations.
NMR isotropic shieldings of 1 and 5′-epi-1 were calculated using WP04/aug-cc-pVDZ/PCM for
1H and mPW1PW91/6-311+G(2d,p) for 13C, which have been shown to be most accurate levels of
theory, among those tested, for NMR data acquired in CD3CN [45]. Average shieldings were obtained
by Boltzmann statistics based on internal energies of conformers. Finally, shieldings were scaled to
chemical shifts using linear regression [25]. The results are reported in Tables S3 and S4. Coupling
constants were calculated at the B3LYP/6-31G(d,p) level and using the keyword "mixed", which
augments the basis set for the calculation of the Fermi Contact term, and averaged by Boltzmann
statistics. The results are reported in Table S4.
Optical rotations of DFT-optimized conformer of 1 were calculated using TDDFT at the
B3LYP/TZVP/PCM(MeOH) level; the results can be found in Table S1. The Boltzmann mean of
individual optical rotations gave [α]D = −105.
4.5. Biological Assays
The bioactivity tests were performed as described previously [23]. The crude extract, the subextracts
and the SPE fractions of the KC subextract were tested in vitro against five human cancer cell lines:
colorectal adenocarcinoma cell line HT-29 (DSMZ, Braunschweig, Germany), malignant melanoma
cell line A-375 (CLS, Eppelheim, Germany), colon cancer cell line HCT-116 (DSMZ, Braunschweig,
Germany), lung carcinoma cell line A-549 (CLS, Eppelheim, Germany), human breast cancer line
MDA-MB-231 (CLS, Eppelheim, Germany), as well as for the non-cancerous human keratinocyte
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line HaCaT (CLS, Eppelheim, Germany) at a concentration of 100 µg/mL. The bioactivity of the
extracts was evaluated by monitoring the metabolic activity using the CellTiterBlue Cell Viability
Assay (Promega, Mannheim, Germany). HT-29 and HaCaT cells were cultivated in RPMI medium,
A-549 and MDA-MB-231 cells in DMEM:Ham’s F12 medium (1:1) supplemented with 15mM HEPES
and A-375 and HCT-116 cells in DMEM medium supplemented with 4.5 g/L D-Glucose and 110 mg/L
sodium pyruvate. All media were supplemented with L-glutamine, 10% fetal bovine serum, 100 U/mL
penicillin, and 100 mg/mL streptomycin. The cultures were maintained at 37 ◦C under a humidified
atmosphere and 5% CO2. The cell lines were transferred every 3 or 4 days. For the experimental
procedure, the cells were seeded in 96-well plates at a concentration of 10,000 cells per well. A stock
solution of 40 mg/mL in DMSO was prepared for each extract. After 24 h incubation, the medium
was removed from the cells and 100 µL fresh medium containing the test samples was added. Each
sample was prepared in duplicate once. Doxorubicin as a standard therapeutic drug was used as a
positive control, 0.5% DMSO and growth media were used as negative controls. Following compound
addition, plates were cultured at 37 ◦C for 24 h. Afterward, the assay was performed according to
the manufacturer’s instructions and measured using the microplate reader Tecan Infinite M200 at
excitation 560 nm and emission of 590 nm. For determination of IC50 values, a dilution series of the
extracts were prepared and tested, as described before for the crude extract. The IC50 values were
calculated by Excel as the concentration that shows 50% inhibition of the viability based on a negative
control (no compound) and compared with the positive control (doxorubicin).
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/18/6/281/s1;
NMR, HRESIMS, and FT-IR spectra of compound 1. Tables with detailed information of computational results.
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